Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women
Status:
Unknown status
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or
placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and
the safety of E4 20 mg (Safety Study Part).